CLINICAL IMMUNOLOGY
Influence of antiphospholipid antibody positivity on glomerular filtration rate markers in a group of systemic sclerosis patients – a 24-month observation
More details
Hide details
Submission date: 2016-03-31
Final revision date: 2016-05-25
Acceptance date: 2016-06-03
Publication date: 2017-08-08
Cent Eur J Immunol 2017;42(2):161-166
KEYWORDS
ABSTRACT
Aim of the study: The aim of the study was the assessment of changes in the glomerular filtration rate (GFR) during long-term observation in a group of systemic sclerosis (SSc) patients with and without chronic antiphospholipid (aPL) antibody positivity.
Material and methods: The observation comprised 50 patients – 23 with diffuse cutaneous SSc – dcSSc and 27 limited cutaneous SSc – lcSSc. After 24 months we assessed 27 patients (9 died, 14 lost follow up); 24 patients (88%) were treated chronically with angiotensin-converting-enzyme inhibitors (ACEIs). Patients were investigated for the presence of aPL: to cardiolipin and to 2 glycoprotein I in IgM and IgG classes. Serum levels of creatinine (S-Cr), cystatin C and creatinine clearance values were determined in all patients. According to the presence of a significant level of at least one of aPL antibodies, pts were divided into groups: group I aPL positive: 14 patients, group II aPL negative – 13 patients.
Results: We did not find significant differences in S-Cr, cystatin C levels and creatinine clearance before and after 24 months of observation between both groups. In follow up observations, the presence of anti-centromere antibodies was significantly more frequent in the aPL positive, as compared to the aPL negative group (p = 0.01). In follow up observations, the level of anticardiolipin antibodies in IgG class was significantly higher in dcSSc compared to lcSSc patients (p = 0.02).
Conclusions: In long-term observation chronic positivity for aPL antibodies does not significantly decrease the GFR in patients with SSc treated with ACEIs.
REFERENCES (21)
1.
Di Franco M, Paradiso M, Riccieri V, et al. (2007): Autonomic dysfunction and microvascular damage in systemic sclerosis. Clin Rheumatol 26: 1278-1283.
2.
Amin A, El-Sayed S, Taher N, Sedki M, et al. (2012): Tc-99m diethylenetriamine pentaacetic acid (DTPA) renal function reserve estimation: is it a reliable predictive tool for assessment of preclinical renal involvement in scleroderma patients? Clin Rheumatol 31: 961-966.
3.
Bose N, Chiesa-Vottero A, Chatterjee S (2015): Scleroderma renal crisis. Semin Arthritis Rheum 44: 687-694.
4.
Gigante A, Rosato E, Massa R, et al. (2012): Evaluation of Chronic Kidney Disease Epidemiology Collaboration equation to estimate glomerular filtration rate in scleroderma patients. Rheumatology (Oxford) 51: 1426-1431.
5.
Rai R, Swetha T (2015): Association of anti-phospholipid antibodies with connective tissue diseases. Indian Dermatol Online J 6: 89-91.
6.
Wielosz E, Dryglewska M, Majdan M (2009): Antiphospholipid antibodies and kidney involvement in patients with systemic sclerosis. Clin Rheumatol 28: 955-959.
7.
Zandman-Goddard G, Tweezer-Zaks N, Shalev T, et al. (2007): A novel overlap syndrome: systemic sclerosis associated with antiphospholipid syndrome–a case series. Ann N Y Acad Sci 1108: 497-504.
8.
Touré AO, Ly F, Sall A, et al. (2013): Antiphospholipid antibodies and systemic scleroderma. Turk J Haematol 30: 32-36.
9.
Gupta R, Thabah MM, Gupta S, et al. (2009): Clinical significance of antiphospholipid antibodies in Indian scleroderma patients. Rheumatol Int 30: 277-279.
10.
Ames PR (2009): Antiphospholipid antibodies in systemic sclerosis: a double oxidative hit? Clin Rheumatol 28: 881-882.
11.
Arslan Tas D (1980): Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23: 581-590.
12.
LeRoy EC, Black C, Fleishmajer R (1988): Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15: 202-204.
13.
Cockroft DW, Gault MH (1976): Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41.
14.
National-Kidney-Fundation (2002): K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 39: S1-S266.
15.
Mohamed RH, Zayed HS, Amin A (2010): Renal disease in systemic sclerosis with normal serum creatinine. Clin Rheumatol 29: 729-737.
16.
Bălănescu P, Lădaru A, Bălănescu E, et al. (2015): Association of anti phosphatidyl ethanolamine antibodies and low complement levels in systemic sclerosis patients – results of a cross-sectional study. Scand J Clin Lab Invest 12: 1-6.
17.
Gigante A, Gasperini ML, Cianci R, et al. (2009): Antiphospholipid antibodies and renal involvement. Am J Nephrol 30: 405-412.
18.
Bussone G, Noel LH, Mouthon L (2011): Renal involvement in patients with systemic sclerosis. Nephrol Ther 7: 192-199.
19.
Morrisroe KB, Stevens W, Nandurkar H, et al. (2014): The association of antiphospholipid antibodies with cardiopulmonary manifestations of systemic sclerosis. Clin Exp Rheumatol 32: 133-137.
20.
Sysa-Jędrzejowska A, Zalewska A, Dziankowska-Bartkowiak B, Waszczykowska E (2004): Evaluation of serum vascular endothelial growth factor and endostatin in systemic sclerosis patients – correlation with lung and cardio-vascular system involvement. Centr Eur J Immunol 29: 15-22.
21.
Milena K. Nikolova-Vlahova, Krasimir V, et al. (2015): Antiphospholipid antibodies in patients with upper-extremity deep vein thrombosis. Centr Eur J Immunol 40: 307-310.